Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen boosts MS drug portfolio
by Ryan Cross
December 4, 2017
| A version of this story appeared in
Volume 95, Issue 48
Biogen will take over development of an Alkermes small-molecule drug for multiple sclerosis (MS). The compound, ALKS 8700, is in Phase III clinical trials and would compete with Biogen’s MS drug Tecfidera. ALKS 8700, based on monomethyl fumarate, is anticipated to have fewer gastrointestinal side effects than Tecfidera, which is based on dimethyl fumarate. Alkermes will get an up-front payment of $28 million and could earn $200 million in milestones, plus royalties.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter